CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
Clinical trial NCT06031727 · RECRUITING
Trial details
- NCT number
- NCT06031727
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-04
- Primary completion
- 2025-06-30
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.